CD8A and neoplasm: Induces ADCC, ADCP and CDC against CD38+ tumour cells (30–32). Daratumumab also induces lysis of CD38+ MDSC, CD38+ Tregs and CD38+ B cells, and increases the absolute counts of CD8+ T cells (33).